Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BiTE Conditioning for ABO-Incompatible Living Donor Kidney Transplantation
ChiCTR2600130091Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Aug 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of teclistamab and blinatumomab in end-stage kidney disease (ESKD) and ABO blood-group incompatibility (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Rate of reaching target decreased ABO blood group antibody titer. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
teclistamabblinatumomab
03
Conditions
end-stage kidney disease (ESKD)ABO blood-group incompatibility
Beyond the preview
Go deeper on ChiCTR2600130091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130091.